Jazwares Cares Celebrates Squishmallows Day With Largest Single Squishmallows Donation to Charities Worldwide
7.3.2025 12:00:00 CET | Business Wire | Press Release
To celebrate the third-annual Squishmallows Day on Friday, March 7, Jazwares Cares, the philanthropic arm of global toy company Jazwares, is thrilled to announce that the largest single Squishmallows donation ever will be given to children and families in need across the U.S., Europe and Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307969506/en/
Jazwares Cares Celebrates Squishmallows Day with Squishmallows Donation (Photo: Business Wire)
“Putting a smile on children’s faces is at the heart of everything we do,” said Laura Zebersky, President and Chief Commercial Officer for Jazwares. “As Squishmallows continues to capture the hearts of fans around the world, what better way to celebrate the third-annual Squishmallows Day than to bring joy to kids who may not have Squishmallows of their own with our largest single Squishmallows donation.”
Paying it forward to all its fans, more than 500,000 loveable, huggable Squishmallows plush will be distributed through children’s hospitals, Title I schools, and Jazwares Cares’ non-profit partners. In the U.S., Jazwares Cares is partnering with The Toy Foundation, Baby2Baby, Toys for Tots, First Responders Children’s Foundation, and more. In Australia, Jazwares is working with the Australian Toy Industry to donate Squishmallows to Backpacks 4 VIC Kids. In Europe, Jazwares will partner with charities In Kind Direct, Innatura, and Dons Solidaires, to provide Squishmallows to children and their families across the UK, Germany, and France respectively.
Jazwares Cares’ mission is to support children's health, well-being, and educational development through play. This is achieved through product donations, sponsorships, education-based programs, and the time and talent of Jazwares employees.
For more information on Jazwares, visit Jazwares on LinkedIn, X, Instagram, Facebook, and www.jazwares.com. For more information on Squishmallows, visit Squishmallows on X, Facebook, Instagram, TikTok, and Squishmallows.com.
ABOUT JAZWARES
Jazwares, a Berkshire Hathaway company, is a leading global toy manufacturer with a robust portfolio of owned and licensed brands. Founded in 1997, Jazwares celebrates imaginative play with a progressive focus on identifying new and relevant trends to transform into high-quality products for consumers of all ages. Jazwares engages consumers through innovative play experiences with popular brands such as Squishmallows™, Pokémon™, Hello Kitty™, Star Wars™, Disney™, BumBumz™, and Adopt Me™. In addition to toys, offerings include virtual games, costumes, and pet products. Headquartered in Plantation, Florida, Jazwares has offices worldwide and sells its products in over 100 countries. For more information, visit www.jazwares.com and follow us on LinkedIn, X, Instagram, and Facebook.
ABOUT SQUISHMALLOWS
Squishmallows debuted in 2017 and has since evolved into a lovable lifestyle brand for fans of all ages. Recent achievements have included 10 Toy of the Year Awards, partnerships with major corporations (H&M, Puma, McDonald’s), and continued fan engagement at events like VidCon Anaheim, San Diego Comic-Con, and the Squish Bus Tour that swept the nation in 2023. With line extensions into apparel and pet products, collaborations with studios like Netflix and Warner Bros., and our global licensing program featuring 90+ partners, Squishmallows looks forward to continuing to expand the Squad, one Squish at a time.
ABOUT SQUISHMALLOWS DAY
We unveiled our first-ever Squishmallows—the iconic Cam the Cat —on March 7th, 2017. The Squishmallows brand took the world by storm later that year, and the rest is history. Whether you’ve been with us from the beginning or are just joining the Squad now, one thing is certain: we couldn’t do it without you. Every year on March 7th, Squishmallows celebrates its growing community and dedicates this day to fans all around the world in the #SquishmallowsSquad.
This release contains disclosures that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. These forward-looking statements are based upon Jazwares' current plans or expectations and are subject to a number of uncertainties and risks. These statements are not guarantees of future performance, and Jazwares has no specific intention to update these statements. As a consequence, current plans, and anticipated actions may differ from those expressed in any forward-looking statements made by Jazwares or on Jazwares’ behalf.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307969506/en/
Contacts
MEDIA CONTACT:
Jazwares
pr@jazwares.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom